Introduction
Adrenomedullin (AM) is a novel hypotensive peptide discovered in pheochromocytoma tissue based on its ability to increase cyclic adenosine monophosphate (cAMP) levels in platelets (1) . Its physiological activities include vasodilation (2, 3) , diuresis (4), natriuresis (5) , inhibition of aldosterone secretion (6, 7) and antiinflammatory activity (8) , and its levels in plasma are elevated in patients with heart failure (9, the circulating plasma AM immunoreactivity (19) . In this regard, Nishikimi et al. reported that AM-m is produced in various organs and released into the blood, and that it is likely cleared by the lungs (20) . In addition, substances such as tumor necrosis factor, interleukin-1, and lipopolysaccharide (LPS) have been shown to stimulate AM gene transcription and protein synthesis (21, 22) .
Recently, immunoradiometric assays (IRMAs) were developed for detection of AM-m and total AM (AM-t) (23, 24) . Although these assays have been used to calculate AMGly (AM-t AM-m), this approach is limited by imprecision of the calculation. Consequently, although AM-Gly is the major AM form in the circulation, neither the mechanisms of its synthesis and secretion nor its physiological functions are fully understood. For this reason, and also because AM-Gly levels in tissue are very low, the development of a direct, ultrasensitive immunoassay for AM-Gly would be of great use.
Ultrasensitive enzyme immunoassays (Immune Complex Transfer Enzyme Immunoassays; ICTEIA) for specific antigens have been developed (25) . The immune complexes consist of three components: a dinitrophenyl (DNP)-biotinylantibody, an antigen and an antibody-labeled enzyme. These three components are first trapped onto an IgG (anti-DNP)-coated solid phase (Capture); then, after washing, they are eluted with DNP-lysine and transferred to a streptavidincoated solid phase (Transfer). Nonspecific signals are markedly reduced by the transfer, thereby improving the sensitivity. To better understand the physiological function and biosynthesis of AM and AM-Gly, we have developed an ICTEIA for AM-Gly. This assay enables direct measurement of AM-Gly levels in plasma and tissues.
Materials and Methods

Adrenomedullin and Its Related Peptides
Rat AM-m, calcitonin gene-related peptide (CGRP) and amylin were purchased from Peptide Institute, Inc. (Osaka, Japan). Rat AM-Gly was from BEX (Tokyo, Japan).
Animals
Male Wistar rats (450-500 g) were purchased from Charles River (Yokohama, Japan) and housed in a room at a temperature of 23 ºC with a 12:12 h light-dark cycle. Standard rodent food and tap water were provided ad libitum.
Animal Treatment
Rats were injected intraperitoneally with either LPS (10 mg per kg of body mass; Escherichia coli; Difco, Detroit, USA) or saline (300 µl; sham). Four hours later they were anesthetized with pentobarbital and killed by exsanguination, and then various organs were removed. A part of each organ was weighed and then boiled in 5-10 ml of distilled water for 10 min. Acetic acid was then added to final concentration of 1 mol/l, after which the boiled tissue was crushed, homogenized for 1 min with a Polytron mixer, and centrifuged at 21,000 g for 30 min. Aliquots (100 µl) of supernatant were then lyophilized.
Samples
Blood samples were withdrawn into plastic syringes containing 1 mg/ml ethylenediamine-N,N,N ,N -tetraacetic acid (EDTA) and 500 kallikrein inhibitory units (KIU)/ml of aprotinin, then quickly transferred to plastic tubes and centrifuged at 2,000 g for 20 min at 4 ºC. The plasma samples were stored at 30 ºC until analyzed.
Buffers
AM buffer contained 50 mmol/l sodium phosphate (pH 7.0), 400 mmol/l NaCl, 0.1% bovine serum albumin (BSA), 1 mmol/l MgCl2, and 0.1% NaN3. AM-Gly buffer consisted of AM buffer supplemented with 0.1% Triton X-100 and 5 mmol/l EDTA. This buffer was used for preparing standard AM-Gly and the conjugate mix and for dissolving lyophilized samples. Buffer A contained 10 mmol/l sodium phosphate (pH 7.0), 100 mmol/l NaCl, 0.01% BSA, 1 mmol/l MgCl2, and 0.1% NaN3.
Preparation of Antibodies
We used three anti-AM monoclonal antibodies (23, 24) : one recognized the ring structure (rAdR-2; anti-rat AM [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] ), one the C-terminal amide structure (AdC-1; anti-AM[46-52]NH2), and one the middle portion (AdM-2; anti-AM [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] ) of the molecule. These antibodies were gifted from Shionogi & Co., Ltd., Osaka, Japan.
A polyclonal antibody recognizing the glycine-extended C-terminal of AM (anti-AM-Cys-[42-52]Gly) was prepared as follows. Maleimide-activated keyhole limpet hemocyamin (10 mg) and N-Cys-AM[42-52]Gly (10 mg) were conjugated for 2 h, after which the reaction mixture was dialyzed four times against 1.0 l of 0.9% NaCl and twice against 1.0 l of 0.05 mol/l sodium phosphate buffer (pH 7.4). It was then emulsified with an equal volume of Freund's complete adjuvant (Difco) and used to immunize New Zealand white male rabbits.
Rabbit (anti-2,4-DNP-BSA) serum was obtained from Shibayagi Co., Ltd. (Shibukawa, Japan).
Monoclonal mouse IgG1 was prepared from ascites using protein-A-Sepharose CL-4B (Pharmacia LKB Biotechnology AB, Uppsala, Sweden) according to the manufacturer's instructions. Rabbit IgG was prepared from antiserum by fractionation with Na2SO4 followed by passage through a diethylaminoethyl (DEAE)-cellulose column. F(ab )2 was prepared by digestion of the IgG and IgG1 with pepsin, after which Fab was prepared by reduction of the F(ab )2. The amounts of IgG, IgG1, F(ab )2, and Fab were calculated from the absorbance at 280 nm (26) .
Preparation of Capture Antibody and Antibody-Labeled Enzyme
Monoclonal mouse anti-AM [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Fab was conjugated with 6-maleimidohexanoyl-2,4 DNP-biotinyl-BSA and used as a capture antibody (26, 27 (26, 27) .
Preparation of Protein-Coated Polystyrene Beads
Polystyrene beads (6.4 mm diameter; MS-7401A beads for enzyme-linked immunosorbent assay (ELISA) Amino type; Sumitomo Bakelite Co., Ltd., Osaka, Japan) were covalently coupled with affinity-purified anti-DNP-BSA IgG (0.01 g/l) and biotinyl-BSA (0.01 g/l) using glutaraldehyde according to the manufacturer's instructions. The affinity-purified anti-DNP-BSA IgG (0.01 g/l) had earlier been eluted from DNP-BSA-Sepharose 4B using 3.2 mmol/l HCl (pH 2.5) (25) . Biotinyl-BSA-covalently coupled polystyrene beads were then coated with streptavidin (0.01 g/l) (25, 28) .
Two-Site ICTEIA for AM-Gly
1) Formation and Trapping of a Capture-Antibody-AntigenAntibody-Enzyme Immune Complex
An aliquot (20 µl) of standard AM-Gly, plasma sample or tissue extract (lyophilized and dissolved in 100 µl of AMGly buffer) was incubated overnight at 4 ºC with 130 µl of AM-Gly buffer containing 50 KIU/ml of aprotinin, 50 fmol of 2,4-DNP biotinyl-BSA-rabbit anti-AM [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] -Fab conjugate, and 50 fmol of rabbit anti-AM[42-52]Gly Fab -β-Dgalactosidase conjugate (first incubation; Formation). Thereafter, one polystyrene bead coated with affinity-purified IgG (anti-DNP-BSA) was added to the mixture and incubated at room temperature (25 ºC) for 30 min with shaking (210 strokes/min; second incubation; Entrapment).
2) Elution and Transfer of the Immune Complex
After removing the incubation mixture, the polystyrene bead was washed twice by addition and aspiration of 3 ml of buffer A and then incubated in 150 µl of buffer A containing 2 mmol/l εN-DNP-L-lysine at room temperature for 30 min with shaking (210 strokes/min; third incubation; Elution). After removal with tweezers, one streptavidin-coated polystyrene bead was added to the eluate and incubated for 30 min at room temperature with shaking (210 strokes/min; fourth incubation; Transfer).
3) Enzyme (Galactosidase) Assay
The bead was then washed as described above, and bound β-D-galactosidase activity was assayed fluorometrically using 4-methylumbelliferyl-β-D-galactoside (4-MUG, 0.3 mmol/l) as a substrate in a 20-h reaction carried out at 30 ºC (26, 27) . The fluorescence intensity was measured with a spectrofluorophotometer (F-3010; Hitachi, Ltd., Tokyo, Japan); the excitation and emission wavelengths were 360 nm and 450 nm, respectively. The fluorescence intensity of 1 10 8 mol/l 4-methylumbelliferone in 0.1 mol/l glycine-NaOH buffer (pH 10.3) was assigned a value of 100.
Two-Site Immunoenzymometric Assay (IEMA) for Rat AM-m and AM-t
To measure rat AM-m, an aliquot (10 µl) of standard AM-m, plasma sample or tissue extract was mixed with 140 µl of AM buffer containing 0.1% Triton X-100, 50 KIU/ml of aprotinin, 10 fmol of 2,4-DNP-biotinyl-BSA-anti-AM [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Fab conjugate (as a capture antibody) and 3 fmol of anti-AM[46-52]NH2 Fab -β-D-galactosidase conjugate (as an antibody-enzyme) and incubated overnight at 4 ºC without shaking (first incubation; Formation). Thereafter, the mixture was incubated with one streptavidin-coated polystyrene bead for 30 min at room temperature with shaking (210 strokes/min, second incubation; Entrapment). After removing the incubation mixture, the bead was washed three times by addition and aspiration of 3 ml of buffer A, and bound β-D-galactosidase activity was assayed fluorometrically as with ICTEIA.
For rat AM-t, 10 fmol of anti AM [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Fab -β-D-galactosidase conjugate (as an antibody-enzyme) was substituted for anti-AM[46-52]NH2 Fab -β-D-galactosidase conjugate, and IEMA was carried out as described above.
Characterization of Rat AM-Gly in Plasma
A plasma sample (2 ml) was loaded onto a Sep-Pak C18 cartridge (Millipore-Waters, Milford, USA) equilibrated with 2 ml of saline and 24 µl of 1 mol/l HCl. After the cartridge was washed with 3 ml of saline and 10% acetonitrile containing 0.1% trifluoroacetic acid (TFA), the absorbed materials were eluted with 4 ml of 60% acetonitrile containing 0.1% TFA. The 3 ml of eluate was then analyzed by reversed-phase high performance liquid chromatography (HPLC) on a TSK ODS 120 Å column (4.6 150 mm; Tosho, Tokyo, Japan) using linear gradient elution with acetonitrile (10% to 60%) in 0.1% TFA over 60 min. An aliquot (50 µl) of each fraction (1 ml/tube) was then lyophilized and dissolved in 100 µl of AM-Gly buffer, and the AM-Gly concentration was measured by ICTEIA.
A plasma sample (2 ml) was separated by Sephadex-G75 chromatography (1.5 120 cm). An aliquot (20 µl or 50 µl) of each fraction (5 ml/tube) was used for measurement of AM-Gly concentration by ICTEIA.
Analytical Evaluation
Data are presented as the means SD. The detection limit for rat AM was expressed as the minimal amount that gave a bound β-D-galactosidase activity significantly higher than the nonspecific activity in the absence of rat AM (background). The statistical significance of that difference was evaluated using a Student's t-test ( p 0.001, AM-Gly: n 6-7; AM-m, AM-t: n 3). Differences between the LPS and sham groups were also evaluated using Student's t-tests.
Results
Immune Complex Transfer Enzyme Immunoassay for Rat AM-Gly
Rat AM-Gly was measured by two-site ICTEIA as shown schematically in Fig. 1 (25, 27) . AM was reacted simultaneously with 2,4-DNP-biotinyl-BSA-anti-AM [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Figure 2 shows a typical calibration curve for rat AM-Gly, AM-m and AM-t. The lower detection limit of AM-Gly was 1 amol/assay; the assay range for plasma was 50 fmol/l (20-µl plasma samples).
Calibration Curve and Sensitivity
Precision
The reproducibility of the ICTEIA was estimated for plasma using two test samples and several standard samples containing different concentrations of AM. The within and betweenday assay coefficients of variation (CVs) were 4.5-14.1% (n 9-10) and 9.9-20.5% (n 10), respectively.
Recovery and Dilution Tests
Analytical recovery of exogenously added AM-Gly from 10 or 20 µl plasma samples was 107.0-116.6% (Table 1) . Moreover, the measured AM-Gly values varied linearly with dilution (Fig. 3) .
Cross-Reactivity
The cross-reactivities of the AM-Gly ICTEIA with AM-m and other peptides similar to AM were then evaluated. The cross-reactivity with rat CGRP and amylin was less than 0.01%; cross-reactivity with AM-m was less than 0.001%. Thus, our ICTEIA detected only AM-Gly (Fig. 4) .
Characterization of Plasma AM-Gly
The reversed-phase HPLC elution profile for plasma extract from a sham group rat is shown in Fig. 5 . Notably, im- (25, 27 munoreactive AM measured by ICTEIA was eluted at a position identical to that of authentic AM-Gly. Gel filtration of the eluted fractions showed the analytical recovery of immunoreactive AM-Gly to be 104% (Fig. 6A) . The AMGly/AM-m ratio indicated that the major molecular form of AM in rat plasma is AM-Gly (Fig. 6B) .
Comparison of Directly Measured and Calculated Levels of AM-Gly in Plasma
When we compared the calculated AM-Gly concentration, obtained by subtracting the concentration of AM-m from AM-t, with the direct assay results, we found that the con- 
Yamaga et al: Direct Measurement of Glycine-Extended Adrenomedullin
S49
Fig. 2. Calibration curves for rat AM-Gly (A), AM-m (B), and AM-t (C). As little as 1 amol/assay of AM-Gly could be detected by ICTEIA. By using IEMA, we detected as little as 3 amol/assay and 1 amol/assay of AM-m and AM-t, respectively. Open and closed circles indicate bound β-D-galactosidase activity (specific nonspecific β-D-galactosidase activity; FI RB) and specifically bound β-D-galactosidase activity (SP.FI), respectively. Closed squares indicate coefficients of variation (CV). rAM, ratAM.
Recovery was calculated with formula: [(b) (a)] /0.1 100. Std, standard.
centrations by direct assay were only 61.4-95.1% of the calculated values ( Table 2 ). The calculated values thus overestimated the actual amount of AM-Gly in plasma, most likely due to the presence of degradated AM fragments.
AM-Gly and AM-m Concentrations in Sham-Group Plasma and Tissue
AM-Gly concentrations in plasma and the indicated tissues from sham-group rats were measured using ICTEIA (Table  3 ). The AM-Gly concentration in plasma was 5.22 2.56 fmol/ml (n 4). In contrast to plasma, tissue levels of AMGly were much lower than those of AM-m (Tables 3-5) .
AM-Gly and AM-m Concentrations in LPS-Group Plasma and Tissue
With the exception of the cardiac atrium, plasma and tissue AM-Gly concentrations were significantly higher in LPStreated rats than in sham-group rats (Table 3) . On the other hand, although the AM-Gly/AM-m ratio tended to be higher in the kidneys of LPS rats, there was generally no significant difference in the AM-Gly/AM-m ratios between LPS and sham rats (Table 5 ).
Discussion
We have developed an ultrasensitive ICTEIA that enables us to measure as little as 1 amol/assay of AM-Gly. There are several reasons why ICTEIA, which was first developed by Hashida and Ishikawa (25) in 1990 as a system for measuring ferritin, is so highly sensitive (27) : first, it is a noncompetitive enzyme immunoassay; second, Fab is conjugated to β-D-galactosidase by a hinge method; third, the enzymatic activity is assayed fluorometrically; and fourth, the transfer Calculated value was calculated with formula: (AM-Gly) (AM-t) (AM-m).
step diminishes nonspecific binding of enzyme-labeled antibody without reducing the size of the solid phase surface or the reaction mixture volume for immunoreactions. Furthermore, despite the very high sensitivity, the reproducibility and stability of this method are comparable to those of IRMA and radioimmunoassay (RIA). Characterization of the immunoreactive AM-Gly detected in rat plasma by our ICTEIA yielded two major peaks on reversed-phase HPLC. The smaller peak, which emerged first, is likely an AM fragment degraded on its N-terminal side (29) . The major peak was eluted later, at a position identical to authentic rat AM-Gly. Thus, immunoreactive AM-Gly in rat plasma detected by our ICTEIA is AM-Gly itself.
Because the AM-Gly concentration calculated by subtracting AM-m from AM-t includes not only AM-Gly but also various degradated AM fragments, direct measurement AMGly is necessary to more precisely characterize the biosynthesis and secretion of AM. Using ICTEIA, the concentration of AM-Gly in rat plasma was found to be substantially higher than that of AM-m, which is consistent with an earlier report that described AM-Gly as the major molecular form of AM in human plasma (19) . Nishikimi et al. Plasma concentration of ir-rAM-m is expressed as fmol/ml. ir-rAM, immunoreactive rat AM. of AM-Gly (30). We do not address the question of AM half-life in this study, but given that the AM-Gly/AM-m ratio was much lower in tissue than in plasma, we suggest that AM is processed and rapidly converted to the mature form in tissues, where it is immediately utilized as an autocrine or paracrine factor. Further study will be required to fully characterize the biosynthesis and physiological functions of AMGly e.g., whether it acts in ways other than as a precursor for AM-m.
We found that the AM-Gly/AM-m ratio in the kidneys was higher than that in other tissues, which may reflect the fact that the α-amidating enzyme activity is relatively lower in this organ than in other tissues (29) . Although low enzyme activity has also been reported in the adrenal glands and lungs, these tissues contain much higher concentrations of AM-m (29) . It is notable in this regard that the lung contains an abundance of binding sites for AM-m (20, 31) , suggesting that differences in the AM-Gly/AM-m ratio among tissues may not be attributed solely to the availability of α-amidating enzyme; the secretion and clearance of AM-Gly and AM-m may also be key determinants.
To investigate changes in secretion induced by morbidity, we evaluated AM-Gly levels in tissues from rats administered LPS. Matsui et al. reported that the mean blood pressure returned to the basal value although the plasma AM levels were 35 times higher than the basal value at 4 h after intravenous injection of LPS (32) . We found that LPS increased the levels of both AM-m and AM-Gly in the lung, cardiac ventricle, kidney, and liver, but not in the cardiac atrium or adrenal gland (Tables 3 and 4 ). The fact that these AM-Gly/AM-m ratios were not significantly affected in any tissue, although they tended to be increased in the kidneys, suggests that AM-Gly processing and conversion to AM-m occurs immediately in these tissues, despite the greater availability of precursor. The lower activity of α-amidating enzyme in the kidneys may induce a slight rise in the AM-Gly concentration, which would account for the tendency of the AM-Gly/AM-m ratio to rise. In the adrenal glands of LPStreated animals, the concentration of AM-m declined as that of AM-Gly increased. This may indicate that AM-m synthesized in the adrenal glands is secreted for use by other organs, and that the adrenal glands are a key source of AM-m in animals in a morbid state.
Based on these results, we conclude that direct assay of AM-Gly in plasma and tissue is now possible using a highly sensitive ICTEIA, and we anticipate that the availability of this assay will enable more precise investigation of the biosynthesis and secretion of AM.
